Different Truncation Methods of AUC between Japan and the EU for Bioequivalence Assessment: Influence on the Regulatory Judgment

  • OISHI Masayo
    Department of Drug Development Science & Clinical Evaluation, Keio University Faculty of Pharmacy
  • CHIBA Koji
    Department of Drug Development Science & Clinical Evaluation, Keio University Faculty of Pharmacy
  • FUKUSHIMA Takashi
    Department of Drug Development Science & Clinical Evaluation, Keio University Faculty of Pharmacy
  • TOMONO Yoshiro
    Department of Drug Development Science & Clinical Evaluation, Keio University Faculty of Pharmacy
  • SUWA Toshio
    Department of Drug Development Science & Clinical Evaluation, Keio University Faculty of Pharmacy

この論文をさがす

説明

In regulatory guidelines for bioequivalence (BE) assessment, the definitions of AUC for primary assessment are different in ICH countries, i.e., AUC from zero to the last sampling point (AUCall) in Japan, AUC from zero to infinity (AUCinf) or AUC from zero to the last measurable point (AUClast) in the US, and AUClast in the EU. To assure sufficient accuracy of truncated AUC for BE assessment, the ratio of truncated AUC (AUCall or AUClast) to AUCinf should be more than 80% both in Japanese and EU guidelines. We investigated how the difference in the definition of truncated AUC affects BE assessment of sustained release (SR) formulation. Our simulation result demonstrated that AUCall/AUCinf could be ≥80% despite AUClast/AUCinf being <80% and AUCall failed to detect formulation difference. In Japanese package inserts of generic drugs in SR formulation, there were products for which AUCall/AUCinf was ≥80% though AUClast/AUCinf was <80%. In conclusion, it was confirmed that the difference in definition of truncated AUC affected the judgment of validity of truncated AUC for BE assessment, and AUCall could fail to detect the substantially different in vivo dissolution profile of generic drugs with SR formulation from the original drug.<br>

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (3)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ